Biopharma firms are in-licensing candidates later according to an industry expert, who says the trend is impacting the contract development and manufacturing sector. In-licensing—the practice of paying for rights to develop and commercialize a product discovered by another company—is a widely used strategy in the biopharmaceutical industry. According to a recent report in Nature, the … Continue reading “The Benefits and Impact of Later In-Licensing Deals for Biopharma”
Author: Gareth Macdonald
Gareth Macdonald is a freelance contributor.
Culture Biosciences Adds $15M for New Software, Bioreactor Expansion
Culture Biosciences, a contract development and manufacturing organization, has added new funding to increase bioreactor capacity and create additional monitoring software. The San Francisco startup announced the completion of a $15 million Series A financing round this week, bringing aboard fresh cash from new venture capital backers in addition to earlier investors. Culture Biosciences said … Continue reading “Culture Biosciences Adds $15M for New Software, Bioreactor Expansion”
New Meds Set to Reshape US CNS and Oncology Markets
CNS and cancer will be biopharma battlegrounds this year according to Philadelphia-based Clarivate Analytics, which says new medicines will reshape the US market. The US Food and Drug Administration (FDA) looks set to approve several innovative therapies for central nervous system (CNS) disorders and cancer in 2020, according to Clarivate (NYSE: [[ticker:CCC]]). The firm cited … Continue reading “New Meds Set to Reshape US CNS and Oncology Markets”
Advanced Therapies Are Reshaping Biopharma R&D: KPMG Report
Biopharmaceutical companies focused on advanced therapies are changing industry R&D, manufacturing, and supply chain models according to KPMG. The audit, tax, and advisory services firm shared details of the trend in its Healthcare & Life Sciences Outlook report, explaining that for companies developing cell, gene, and nucleic acid-based therapies, innovation is a necessity. “As pharmaceutical … Continue reading “Advanced Therapies Are Reshaping Biopharma R&D: KPMG Report”
AstraZeneca Chooses China for R&D and AI Centers, $1B Biotech Fund
AstraZeneca says it will establish centers for drug research and artificial intelligence development in China. The pharmaceutical giant has also set up a $1 billion fund to foster biotech innovation in that country. The move—which was announced at the China International Import Expo this week—will see AstraZeneca found a global R&D center in Shanghai’s central … Continue reading “AstraZeneca Chooses China for R&D and AI Centers, $1B Biotech Fund”